Aardvark Therapeutics (AARD) Change in Account Payables (2024 - 2026)

Aardvark Therapeutics has reported Change in Account Payables for 3 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Change in Account Payables rose 273.61% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 6.4% YoY) and the FY2025 annual result came in at $239000.0, down 70.05% from the prior year.
• Change in Account Payables climbed to $2.4 million in Q1 2026 per AARD's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $2.6 million in Q2 2025 and troughed at -$2.4 million in Q4 2025.
• A 3-year average of $384222.2 and a median of $634000.0 in 2024 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 306.15% in 2025, down 298.83% in 2025.
• Over 3 years, Change in Account Payables stood at $1.2 million in 2024, then slumped by 298.83% to -$2.4 million in 2025, then soared by 202.07% to $2.4 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.4 million, -$2.4 million, and -$612000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.